Simulations Plus, Inc. SLP
We take great care to ensure that the data presented and summarized in this overview for Simulations Plus, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SLP
View all-
Black Rock Inc. New York, NY2.51MShares$121 Million0.0% of portfolio
-
Conestoga Capital Advisors, LLC2.26MShares$109 Million1.36% of portfolio
-
Neuberger Berman Group LLC New York, NY1.3MShares$62.7 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.14MShares$54.8 Million0.0% of portfolio
-
Ranger Investment Management, L.P. Dallas, TX835KShares$40.3 Million2.26% of portfolio
-
State Street Corp Boston, MA618KShares$29.8 Million0.0% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN488KShares$23.5 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA461KShares$22.3 Million0.0% of portfolio
-
Ophir Asset Management Pty LTD440KShares$21.2 Million3.37% of portfolio
-
Morgan Stanley New York, NY435KShares$21 Million0.0% of portfolio
Latest Institutional Activity in SLP
Top Purchases
Top Sells
About SLP
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
Insider Transactions at SLP
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 14
2024
|
Lisa La Vange Director |
SELL
Open market or private sale
|
Direct |
500
-6.35%
|
$25,000
$50.0 P/Share
|
May 14
2024
|
Daniel L Weiner Director |
SELL
Open market or private sale
|
Direct |
3,000
-27.88%
|
$150,000
$50.13 P/Share
|
May 14
2024
|
Daniel L Weiner Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+15.68%
|
$68,000
$34.23 P/Share
|
May 07
2024
|
Daniel L Weiner Director |
SELL
Open market or private sale
|
Direct |
3,250
-27.06%
|
$156,000
$48.31 P/Share
|
May 07
2024
|
Daniel L Weiner Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+14.28%
|
$68,000
$34.23 P/Share
|
May 07
2024
|
Lisa La Vange Director |
SELL
Open market or private sale
|
Direct |
650
-7.63%
|
$31,200
$48.3 P/Share
|
May 01
2024
|
Sharlene Evans Director |
BUY
Grant, award, or other acquisition
|
Direct |
662
+9.74%
|
-
|
May 01
2024
|
Walter S Woltosz Director |
SELL
Open market or private sale
|
Direct |
20,000
-0.28%
|
$900,000
$45.78 P/Share
|
May 01
2024
|
Walter S Woltosz Director |
BUY
Grant, award, or other acquisition
|
Direct |
662
+0.02%
|
-
|
May 01
2024
|
Lisa La Vange Director |
BUY
Grant, award, or other acquisition
|
Direct |
662
+7.21%
|
-
|
May 01
2024
|
Daniel L Weiner Director |
BUY
Grant, award, or other acquisition
|
Direct |
662
+6.2%
|
-
|
May 01
2024
|
John Kenneth Paglia Director |
BUY
Grant, award, or other acquisition
|
Direct |
662
+15.71%
|
-
|
Apr 01
2024
|
Walter S Woltosz Director |
SELL
Open market or private sale
|
Direct |
20,000
-0.28%
|
$800,000
$40.48 P/Share
|
Mar 01
2024
|
Walter S Woltosz Director |
SELL
Open market or private sale
|
Direct |
20,000
-0.27%
|
$820,000
$41.55 P/Share
|
Feb 02
2024
|
Walter S Woltosz Director |
SELL
Open market or private sale
|
Direct |
1,055
-0.03%
|
$39,035
$37.64 P/Share
|
Feb 01
2024
|
Walter S Woltosz Director |
SELL
Open market or private sale
|
Direct |
18,945
-0.26%
|
$719,910
$38.24 P/Share
|
Feb 01
2024
|
Daniel L Weiner Director |
BUY
Grant, award, or other acquisition
|
Direct |
792
+7.81%
|
-
|
Feb 01
2024
|
John Kenneth Paglia Director |
BUY
Grant, award, or other acquisition
|
Direct |
792
+21.52%
|
-
|
Feb 01
2024
|
Sharlene Evans Director |
BUY
Grant, award, or other acquisition
|
Direct |
792
+12.64%
|
-
|
Feb 01
2024
|
Lisa La Vange Director |
BUY
Grant, award, or other acquisition
|
Direct |
792
+9.15%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 14.5K shares |
---|---|
Exercise of conversion of derivative security | 4.23K shares |
Bona fide gift | 85K shares |
---|---|
Open market or private sale | 257K shares |